Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563901 · ClinicalTrials.gov registry record
Analyzing How Genetics May Affect Response to High Blood Pressure Medications
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 37,939
- Enrollment target
NCT00563901 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 37,939 participants.
The verdict
NCT00563901 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 37,939 participants
- Enrollment target
Study Summary
High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. It is believed that genetic variations may contribute to the inconsistent treatment response. This study will use genetic analysis to determine whether particular genes interact with high blood pressure medications to modify the risk of certain cardiovascular diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,939 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563901
The ClinicalTrials.gov registry entry for NCT00563901 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37,939 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00563901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00563901 about?
NCT00563901 is a clinical study titled "Analyzing How Genetics May Affect Response to High Blood Pressure Medications". High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. It is believed that genetic variations may contribute to the inconsistent treatment r...
What is the current status of trial NCT00563901?
This trial is currently completed. The enrollment target is 37,939 participants. The study started on 2000-09. Estimated completion is 2004-05.
Who is sponsoring clinical trial NCT00563901?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.